Momelotinib therapy for myelofibrosis: a 7-year follow-up.

about

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors

P2860

Q58801187-476AB30C-3591-4917-8E25-9CD9423FE420

P2860

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

Item

http://www.wikidata.org/entity/Q54998956

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@en

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@nl

type

Item

label

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@en

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@nl

prefLabel

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@en

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

@nl

P1476

Momelotinib therapy for myelofibrosis: a 7-year follow-up

@en

P2093

Animesh Pardanani

http://www.w3.org/2001/XMLSchema#string

Ayalew Tefferi

http://www.w3.org/2001/XMLSchema#string

Curtis A Hanson

http://www.w3.org/2001/XMLSchema#string

Daniela Barraco

http://www.w3.org/2001/XMLSchema#string

Kebede H Begna

http://www.w3.org/2001/XMLSchema#string

Mark R Litzow

http://www.w3.org/2001/XMLSchema#string

Naseema Gangat

http://www.w3.org/2001/XMLSchema#string

Rhett P Ketterling

http://www.w3.org/2001/XMLSchema#string

Sahrish Shah

http://www.w3.org/2001/XMLSchema#string

Terra L Lasho

http://www.w3.org/2001/XMLSchema#string

P2860

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.

Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.

Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib.

P2888

s41408-018-0067-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41408-018-0067-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

W Hogan

Aref Al-Kali

P577

2018-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515114

http://www.w3.org/2001/XMLSchema#string

P921

momelotinib

P932

5841331

http://www.w3.org/2001/XMLSchema#string

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

about

P2860

P2860

Momelotinib therapy for myelofibrosis: a 7-year follow-up.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932